GlassScriptPhysician profile
Richard S Rosenberg
NPI 1598766636
$14,542.82
in general payments reported to CMS, 2019-2025
80 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,061 · 2020: $1,522 · 2021: $2,147 · 2022: $2,638 · 2023: $2,286 · 2024: $2,196 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,957 · Consulting Fee: $150 · Education: $68.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,957.18 |
| Consulting Fee | $150.00 |
| Education | $68.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,542.85 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,330.89 | 2019-2025 | |
| Biogen, INC. | $1,044.73 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Teva Pharmaceuticals USA, INC. | $1,024.59 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Allergan, INC. | $660.69 | 2019-2022 | |
| Celgene Corporation | $522.27 | 2022-2025 | Zeposia |
| Csl Behring | $522.22 | 2019-2025 | Hizentra |
| Ucb, INC. | $476.63 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Pfizer INC. | $426.21 | 2019-2025 | |
| Eisai INC. | $424.95 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $408.78 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $385.61 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $362.53 | 2019-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $282.50 | 2019-2021 | |
| Argenx US, INC. | $281.18 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 79 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.